Axogen, Inc. (AXGN)

Axogen's stock (AXGN) has experienced significant movement in the past six months. As of April 10, 2026, the stock price was $31.96, with a 52-week range between $9.21 and $36.00. The share price on April 2, 2026, was $34.44, representing a 107.22% increase from $16.62 on April 7, 2025. Key events include the FDA BLA approval for Avance, which incurred one-time costs, an upsized share offering in January 2026, and strong financial results for the fourth quarter and full year of 2025. The company expects to be free cash flow positive for the full-year 2026, with projected revenue growth of at least 18%.

The provided information does not explicitly detail the demand seasonality for Axogen, Inc.'s products and services. Axogen's focus on peripheral nerve regeneration and repair for traumatic injuries and surgical procedures might suggest a relatively consistent demand, though surgical volumes could experience some fluctuations throughout the year.

Axogen, Inc. is a medical technology company focused on peripheral nerve regeneration and repair. Its primary industry is Biotechnology, within the Life Sciences and Medical Devices verticals. The company provides solutions for surgeons and healthcare providers to restore nerve function and improve the quality of life for patients with peripheral nerve injuries. Axogen's major products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Avive Soft Tissue Membrane and Avive+ Soft Tissue Matrix, Axotouch Two-Point Discriminator, Acroval Neurosensory and Motor Testing System, and Axoguard HA+ Nerve Protector.

Axogen is headquartered in Alachua, Florida, with a corporate campus in Tampa, Florida. It has a global distribution center in Burleson, Texas, and a global processing center in Vandalia, Ohio. Axogen's products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other European and international countries.

Axogen's brand reputation appears positive, driven by the FDA approval of Avance and a positive outlook from analysts. Analysts generally have a "Moderate Buy" consensus rating for Axogen, with an average price target of $39.75. The company's strong revenue growth and expectation of achieving profitability and positive net cash flow in 2025 further contribute to a favorable reputation. However, Axogen has an ESG risk rating of 31.1, categorized as "High Risk" as of April 4, 2026.

Axogen, Inc. is owned by a mix of institutional and individual shareholders. Institutional shareholders hold 82.10% of the company, while Axogen insiders hold 53.38%. Major institutional owners include First Light Asset Management, LLC, BlackRock, Inc., Vanguard Group Inc, Morgan Stanley, ArrowMark Colorado Holdings LLC, Assenagon Asset Management S.A., Soleus Capital Management, L.P., Geode Capital Management, Llc, State Street Corp, and Millennium Management Llc. Notable individual owners include Guido J. Neels, Joseph M. Mandato, Ew Healthcare Partners LP, and James E. Flynn.